Know Cancer

forgot password

Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV)

Phase 2
18 Years
65 Years
Open (Enrolling)
Chronic Hepatitis C, Chronic Hepatitis B

Thank you

Trial Information

Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV)

(i). Chronic hepatitis B

Chronicity of HBV following acute infection is strongly age-related; the majority (90%) of
infants acquiring HBV perinatally go on to develop chronic infection, while most persons who
acquire HBV later in life resolve their infection [ref 1]. Patients with chronic HBV have a
15-25% lifetime risk of liver cirrhosis and hepatic cancer. An estimated 5,000 people die
each year from complications of chronic HBV infection (cirrhosis and hepatocellular

Three drugs have been approved by the Food and Drug Administration (FDA) for treatment of
chronic HBV: interferon-α (IFN-α), lamivudine, and adefovir dipivoxil. Only one-third of
chronic HBV patients develop a sustained response to IFN-α treatment, and adverse effects
are common [ref 2]. Use of the newer orally-administered nucleoside analogues (lamivudine or
adefovir dipivoxil) typically causes rapid initial clearance of virus and is associated with
fewer adverse effects; however, seroconversion rates are low, and long-term therapy with
lamivudine (required for sustained responses) frequently results in resistance [ref 2].
Adefovir dipivoxil has, so far, not shown the high rate of resistance observed with
lamivudine, but it is expected that resistance will eventually develop [ref 3]. In summary,
major problems with currently approved therapy of HBV include expense, toxicity, and
development of resistance.

(ii). Chronic hepatitis C

Chronic viral hepatitis due to hepatitis C is an enormous medical problem, affecting
approximately 170 million people worldwide (WHO) [ref 4]. In the U.S., an estimated 2.7
million people suffer from chronic HCV, with 10,000-12,000 deaths per year attributable to
the disease (ref 5). Chronic HCV infections in the U.S. are usually acquired through
injectable drug use, sexual contact, or receipt of contaminated blood products (before
antibody screening was initiated in 1990). Most persons exposed to HCV (75%) develop
asymptomatic chronic infection. Eventually, 15%-20% will die of cirrhosis and liver cancer
without intervention [ref 4].

Only two drugs are licensed for treatment of chronic hepatitis C: IFN-α (standard or
pegylated) and ribavirin. Sustained responses to IFN-α monotherapy have occurred in up to
35% of patients; higher responses can be observed with combination treatment (pegylated
IFN-α and ribavirin) [ref 6,7]. Responses to combination therapy is closely linked with HCV
genotype (types 2 and 3 most responsive). A significant number of patients relapse or do not
respond to standard treatment, and retreatment is typically less effective than initial
therapy [ref 8].

(iii). 4-methlyumbelliferone

Umbelliferones (7-hydroxycoumarins) [ref 9] are substances present in many species of
plants, especially umbelliferae, fabaceae, and oleaceae, which include such common plants as
manna ash, sweet woodruff, German chamomile, celery, parsley, and others. In nature,
umbelliferones help protect plants from cellular damage, infestation, trauma, and infection.
Their 7-hydroxycoumarin derivatives (4-methylumbelliferones) [ref 10] are used in liver
therapy, as reagents, plant growth factors, sunscreens, choleretics, and spasmolytics. They
are also used as light-protective agents, in the calibration of medical lasers, and in
analytical chemistry for the quantitation of nitric acid.

Products containing 4-methylumbelliferone as their active substance have been available in
the USA and Europe since 1990, as dietary supplements (under trade names Heparvit®,
Heparmed®, DetoxPro®). These products are promoted as supporting liver function and
improving detoxification. In many parts of Europe, products containing 4-methylumbelliferone
are also available as drugs, and used as spasmolytics and choleretics [ref 11] (improving
liver detoxification systems through increased bile production).

7-hydroxycoumarins are also natural metabolites in the body that play important roles in the
metabolism of ethanol, chemotherapeutic drugs, acetaminophen, anabolic steroids, and other
hepatotoxic drugs [ref 12]. Indeed, measurement of concentrations of 4-methylumbelliferyl
glucuronide (a metabolic product of 4-methylumbelliferone) is a common assay for determining
the level of toxicity of liver-toxic drugs [ref 13].

The broad potential medical benefits of 4-methylumbelliferone as a hepatoprotectant,
anti-inflammatory agent, chemotherapeutic agent, and antiviral substance have been described
[ref 13,14]. More recent studies indicate that 4-methylumbelliferone (and other
7-hydroxycoumarin derivatives) may be effective against Helicobacter pylori [ref 15],
several types of cancer [ref 15-19], and Alzheimer’s disease [ref 20].

Inclusion Criteria:

- Serum ALT at least 1.5x the upper limit of normal

- For chronic HBV: Known positive serum HBeAg for at least 6 months; Presence of HBV
DNA in serum

- For chronic HCV: Presence of anti-HCV in serum within 6 months of enrollment;
Positive serum HCV RNA (enrollment)

- Written informed consent

Exclusion Criteria:

- Treatment (within past 3 months) with interferon, ribavirin, lamivudine, entecavir,
or adefovir dipivoxil

- Current treatment with any drug or dietary supplement that could affect serum
transaminase values (e.g., milk thistle)

- Pregnancy or inability to practice contraception in patients capable of bearing or
fathering children

- Decompensated liver disease (as indicated by total bilirubin >4 mg/dL; albumin <3
g/dL; prolonged (>2 sec over control) prothrombin time; or history of bleeding
esophageal varices, ascites or hepatic encephalopathy)

- Active alcohol use, drug abuse, and/or psychiatric problems that, in the
investigator's opinion, could interfere with participation in the study

- Hepatitis D infection (for HBV-infected patients)

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Reduction of virus in blood to undetectable levels;

Principal Investigator

Charles T Leach, Prof. M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Texas Health Science Center : Department of Pediatrics


United States: Food and Drug Administration

Study ID:

UTHSCSA 045-900-246



Start Date:

September 2005

Completion Date:

August 2007

Related Keywords:

  • Chronic Hepatitis C
  • Chronic Hepatitis B
  • hcv
  • hbv
  • methylumbelliferone
  • liver
  • hepatitis
  • viral
  • heparvit
  • hiv
  • aids
  • Hepatitis
  • Hepatitis A
  • Hepatitis B
  • Hepatitis, Chronic
  • Hepatitis C
  • Hepatitis B, Chronic
  • Hepatitis C, Chronic



University Health Center Downtown "Brady/Green", 527 North Leona, San Antonio, Texas  78207